계명대학교 의학도서관 Repository

The effects of lobeglitazone on glycaemic control and lipid metabolism in high-fat diet-induced diabetic mice

Metadata Downloads
Affiliated Author(s)
박재형조호찬
Alternative Author(s)
Park, Jae HyungCho, Ho Chan
Journal Title
Diabetologia
ISSN
0012-186X
Issued Date
2017
Abstract
Background and aims: The aim of this study was to compare the effects
of lobeglitazone, a novel peroxisome proliferator-activated receptor-γ
agonist, on glycemic control and lipid metabolism with pioglitazone in
mice with type 2 diabetes.We also determined the effects of lobeglitazone
and pioglitazone on glucose uptake, translocation of GLUT4 and AMPK
activity in 3T3L-1 adipocytes.
Materials and methods: 4-week-old C57BL/6 mice were treated with a
high-fat diet for 8 weeks. After 8 weeks of high-fat diet, lobeglitazone or
pioglitazone was administered once daily by oral gavage for 6 weeks.
Results: Low-dose lobeglitazone (1 mg/kg) improved fasting blood glucose
and insulin levels, HOMA-IR index, and blood triglyceride levels
while low-dose pioglitazone did not. In 3T3L-1 cells, low-dose
lobeglitazone (1 μM) significantly increased cellular glucose uptake
and, GLUT4 translocation. Pioglitzone exhibited similar effects at only
high dose treatment (10 μM). High-dose lobeglitazone (10 μM) increased
total cellular GLUT4 protein content while pioglitazone did not. In subcutaneous
fat and 3T3L-1 cells, relativemRNA expression levels for lipid
synthesis were increased in both lobeglitazone and pioglitazone-treated
groups compared to vehicle-treated group, but mRNA expression levels
of β-oxidation-related genes and the energy expenditure-related genes
were significantly increased in lobeglitazone-treated group compared to
pioglitazone-treated group. In addition, lobegitazone treatment significantly
increased phosphorylation of the AMP-activated protein kinase
compared to pioglitazone treatment in 3T3L-1 cells.
Conclusion: These results indicate that low-dose treatment of
lobeglitazone might be enough to improve glucose intolerance while
pioglitazone dose not. In addition, lobeglitazone could improve lipid
metabolism by stimulating β-oxidation and the energy expenditure
through activation of AMPK in adipocyte.
Disclosure: H. Kim: None.
Department
Dept. of Physiology (생리학)
Dept. of Internal Medicine (내과학)
Publisher
School of Medicine (의과대학)
Citation
H. Kim et al. (2017). The effects of lobeglitazone on glycaemic control and lipid metabolism in high-fat diet-induced diabetic mice. Diabetologia, 60(suppl.1), S259–S259. doi: 10.1007/s00125-017-4350-z
Type
Article
ISSN
0012-186X
DOI
10.1007/s00125-017-4350-z
URI
https://kumel.medlib.dsmc.or.kr/handle/2015.oak/41521
Appears in Collections:
1. School of Medicine (의과대학) > Dept. of Internal Medicine (내과학)
1. School of Medicine (의과대학) > Dept. of Physiology (생리학)
Authorize & License
  • Authorize공개
  • EmbargoForever
Files in This Item:

Items in Repository are protected by copyright, with all rights reserved, unless otherwise indicated.